Beyond Air (XAIR) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
23 Mar, 2026Technology and product overview
LungFit PH uses patented Plasma Pulse Technology to generate unlimited nitric oxide (NO) from ambient air, eliminating the need for cylinders or chemicals and enabling rapid therapy initiation in under one minute.
The system is FDA and CE approved for treating hypoxic respiratory failure in neonates and peri-/post-operative pulmonary hypertension, with a flexible commercial model offering monthly service or capital purchase.
Generation II device is lighter, transport-ready, MRI-conditional, and features improved usability, alarms, and maintenance intervals, with FDA review pending.
Sustainability is integral, with no hazardous materials, reduced emissions, and minimal energy use, supporting hospital environmental initiatives.
Patent portfolio includes 17 issued and 8 pending patents, covering core technology and extending protection potentially through 2044.
Market opportunity and commercial execution
U.S. market for LungFit PH is estimated at $350M, with global opportunity exceeding $700M and anticipated to surpass $1B.
Achieved 105% revenue growth for the quarter ending December 2025 compared to the previous year.
Distributor contracts signed in 21 countries, with representation in 40 countries and repeat orders received.
FY 2026 revenue guidance is $8–10 million, with $22.3 million in cash and $22 million in debt as of December 2025.
Anticipates significant market share gains with the launch of LungFit PH II following FDA approval.
Competitive advantages
LungFit PH offers unlimited NO supply from room air, no storage requirements, and rapid setup compared to cylinder and cassette-based systems.
Enhanced safety features include a built-in NO2 smart filter and active alarms, with no need for water traps or hazardous material handling.
Simpler clinical workflows and reduced maintenance improve efficiency and patient care time.
Device is lighter and more compact than competitors, with the second generation weighing as little as 24 lbs.
Latest events from Beyond Air
- Vote on a reverse stock split to maintain Nasdaq listing and authorize meeting adjournment if needed.XAIR
Proxy filing24 Apr 2026 - Q3 revenue up 105% YoY, net loss narrowed, and global expansion continues.XAIR
Q3 202613 Apr 2026 - Revenue grew to $1.2M, guidance lowered, and regulatory delays impacted margins.XAIR
Q4 20243 Feb 2026 - Offering up to 7.86M shares for resale, with proceeds from warrant exercises for corporate use.XAIR
Registration Filing30 Jan 2026 - Second-generation nitric oxide device targets major U.S. and global market share growth.XAIR
2nd Annual Lytham Partners Healthcare Investor Summit15 Jan 2026 - LungFit PH revolutionizes NO therapy with on-demand generation, global reach, and expanding clinical pipeline.XAIR
Corporate presentation15 Jan 2026 - Hospital client base grew 60% and revenue quadrupled, with losses narrowed and cash runway extended.XAIR
Q2 202515 Jan 2026 - CE Mark approval, new partnerships, and next-gen product set stage for global growth in 2025-27.XAIR
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026 - Innovative nitric oxide system drives growth, global expansion, and pipeline progress.XAIR
Lytham Partners 2025 Investor Healthcare Summit10 Jan 2026